Ptc Therapeutics (PTCT) Invested Capital (2012 - 2026)

Ptc Therapeutics' Invested Capital history runs 12 years deep, the most recent figure standing at $314.2 million for Q2 2026.

• In Q2 2026, Invested Capital rose 1537.3% year-over-year to $314.2 million; the TTM figure through Jun 2026 stood at $641.8 million (up 757.28% YoY), while the FY2025 annual figure was $6.0 million, down 67.7% from the prior year.
• Invested Capital for Q2 2026 stood at $314.2 million, up from $305.0 million in the prior quarter.
• The five-year high for Invested Capital was $314.2 million in Q2 2026, with the low at $6.0 million in Q4 2025.
• The 5-year median for Invested Capital is $19.3 million (2023), against an average of $53.6 million.
• The sharpest annual moves came in 2022 and 2026: Invested Capital slumped 85.77% in 2022, then soared 1537.3% in 2026.
• Ptc Therapeutics' Invested Capital stood at $72.1 million in 2022, then plunged by 72.02% to $20.2 million in 2023, then fell by 7.98% to $18.6 million in 2024, then slumped by 67.7% to $6.0 million in 2025, then soared by 5136.92% to $314.2 million in 2026.
• Business Quant data shows PTCT's Invested Capital at $314.2 million in Q2 2026, $305.0 million in Q1 2026, and $6.0 million in Q4 2025.